Clinical Trial Update: Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host Disease [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for glasdegib in refractory sclerodermoid chronic graft-versus-host disease (CGVHD) across Phase 1 and Phase 2 environments.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sclerodermoid Chronic Graft-versus-host Disease

Drugs mentioned

• Glasdegib (glasdegib)

Snippet

Sponsor: Grupo Espanol de trasplantes hematopoyeticos y terapia celular | Conditions: Sclerodermoid Chronic Graft-Versus-Host Disease (Disorder) | Phase 1, Phase 2 | Status: UNKNOWN